Enhanced Intranasal Delivery of Atorvastatin via Superparamagnetic Iron-Oxide-Loaded Nanocarriers: Cytotoxicity and Inflammation Evaluation and In Vivo, In Silico, and Network Pharmacology Study for Targeting Glioblastoma Management

Усиленная интраназальная доставка аторвастатина с помощью нанонесущих систем, нагруженных суперпарамагнитным оксидом железа: оценка цитотоксичности и воспаления, а также исследование in vivo, in silico и с использованием сетевой фармакологии для таргетной терапии глиобластомы
Mahmoud H. M. Teaima, Sammar Fathy Elhabal, Mohamed A. El-Nabarawi, Kristina Zarif Attalla, Doaa H. Hassan, Carol Yousry, Mohamed Adel Said
2025-03-16

atorvastatin nanostructured lipid carriersglioblastoma multiformeintranasal drug deliverynetwork pharmacologysuperparamagnetic iron oxide nanoparticles
Objective: This study aims to develop an intranasal (IN) delivery system for glioblastoma multiforme (GBM) management using repurposed superparamagnetic iron-oxide (SPION) loaded with atorvastatin (ATO)-nanostructured lipid carrier (NLC). Methods: Emulsification and ultrasonication were used to formulate ATO-NLCs, and the best formula was loaded with SPION to make the final atorvastatin/superparamagnetic iron oxide-loaded nanostructured lipid carrier (ASN) formulation. Entrapment efficiency (EE%), particle size (PS), zeta potential (ZP), and drug release after 6 h (Q6h) were evaluated for NLCs. ASN was tested for cytotoxicity on T98G cancer cells, and the cell cycle was examined to determine cell death. Furthermore, the ability of the optimal formulation to suppress the levels of inflammatory biomarkers was investigated in Lipopolysaccharide (LPS)-induced inflammation. The brain-targeting behavior of IN-ASN was visualized in rabbits via confocal laser scanning microscopy (CLSM). Results: The optimum NLC exhibited a spherical shape, EE% of 84.0 ± 0.67%, PS of 282.50 ± 0.51 nm, ZP of −18.40 ± 0.15 mV, and Q6h of 89.23%. The cytotoxicity of ASN against cancer cells was 4.4-fold higher than ATO suspension, with a 1.3-fold increment in cell apoptosis. ASN showed significantly reduced pro-inflammatory biomarkers (IL-β, IL-6, TNF-α, TLR4, NF-қB), whereas CLSM revealed enhanced brain delivery with no observed histopathological nasal irritation. The in silico analysis demonstrated enhanced ATO-ADME (absorption, distribution, metabolism, and excretion) properties, while the network pharmacology study identified 10 target GBM genes, among which MAPK3 was the most prominent with a good binding score as elucidated by the simulated docking study. Conclusions: These findings may present ATO/SPION-NLCs as significant evidence for repurposing atorvastatin in the treatment of glioblastoma multiforme.
1
ASN exhibited 4.4-fold higher cytotoxicity against T98G glioblastoma cells than atorvastatin suspension and increased apoptosis 1.3-fold.
2
ASN significantly reduced inflammatory biomarkers IL-1β, IL-6, TNF-α, TLR4, and NF-κB in an LPS-induced inflammation model.
3
An intranasal atorvastatin nanostructured lipid carrier loaded with superparamagnetic iron oxide was developed for glioblastoma management.
4
Confocal imaging demonstrated enhanced brain delivery after intranasal administration without observed histopathological nasal irritation.
5
In silico analyses predicted improved atorvastatin ADME properties; network pharmacology identified 10 GBM-related genes, with MAPK3 showing the strongest prominence and favorable docking.
6
The findings support atorvastatin/SPION-loaded nanocarriers as a potential repurposed intranasal strategy for glioblastoma treatment.
7
The optimized carrier showed 84.0 ± 0.67% entrapment efficiency, 282.50 ± 0.51 nm particle size, −18.40 ± 0.15 mV zeta potential, and 89.23% six-hour drug release.

Intranasally administered atorvastatin/superparamagnetic iron-oxide-loaded nanostructured lipid carriers (IN-ASN) for glioblastoma multiforme management

Brain-targeting delivery, cytotoxicity, apoptosis, anti-inflammatory activity, and glioblastoma-related molecular targets of IN-ASN

Publication Details
Publication Date
2025-03-16
Journal
Publisher
ISSN
Cited by
33
Access Type
Author Information
Authors
Mahmoud H. M. Teaima
Sammar Fathy Elhabal
Mohamed A. El-Nabarawi
Kristina Zarif Attalla
Doaa H. Hassan
Carol Yousry
Mohamed Adel Said
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%